Neuland Labs.

{
  "main_header": {
    "sid": 229993,
    "name": "Neuland Labs.",
    "stock_name": "Neuland Labs.",
    "full_name": "Neuland Laboratories Ltd",
    "name_url": "stocks-analysis/neuland-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "16,626.50",
    "chg": -146.95,
    "chgp": "-0.88%",
    "dir": -1,
    "prev_price": "16,773.45",
    "mcapval": "21,849.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524558,
    "symbol": "NEULANDLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE794A01010",
    "curr_date": "May 20",
    "curr_time": "",
    "bse_nse_vol": "32.67 k",
    "exc_status": "Active",
    "traded_date": "May 20, 2026",
    "traded_date_str": "2026 05 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/neuland-labs-229993-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Neuland Laboratories Falls 6.35%: 4 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-falls-635-4-key-factors-driving-the-weekly-decline-3995541",
        "imagepath": "",
        "date": "2026-05-17 13:00:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Stock opens at Rs.17,548.30, declines 0.82%</p>\n                    <p><strong>12 May:</strong> Sharp drop of 3.12% amid low volume</p>\n                    <p><strong>13 May:</strong> Strong gap up and record quarterly results announced</p>\n                    <p><strong>14 May:</strong> Partial recovery with 1.51% gain</p>\n                    <p><strong>15 May:</strong> Week closes at Rs.16,570.70, down 0.79%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.17,548.30</div></div>\n                    <div class=\"stat-item\"><div class=\"stat..."
      },
      {
        "title": "Neuland Laboratories Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/neuland-laboratories-ltd-is-rated-buy-3995475",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_mojoScore_3995475.png",
        "date": "2026-05-17 10:10:03",
        "description": "Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Are Neuland Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-neuland-laboratories-ltd-latest-results-good-or-bad-3989938",
        "imagepath": "",
        "date": "2026-05-13 19:17:02",
        "description": "Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters.\n\nHowever, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf..."
      },
      {
        "title": "Neuland Laboratories Q4 FY26: Stellar Quarter Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/neuland-laboratories-q4-fy26-stellar-quarter-masks-valuation-concerns-3989574",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_quaterlyResult_3989574.png",
        "date": "2026-05-13 10:01:41",
        "description": "Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs, has delivered an exceptional fourth quarter for FY26, posting a net profit of ₹212.67 crores—a staggering 424.21% surge quarter-on-quarter and 664.72% year-on-year. The ₹21,766.42-crore market cap company saw revenues soar to ₹776.25 crores in Q4 FY26, marking a 76.54% sequential jump and 136.40% annual growth. However, the stock's muted response—down 0.21% to ₹16,965.40 following the results—suggests investors are grappling with the company's elevated valuation multiples, including a price-to-earnings ratio of 123 times trailing earnings."
      },
      {
        "title": "Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-sees-robust-trading-activity-amid-sector-outperformance-3989076",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_most_active_equities_by_value_3989076.png",
        "date": "2026-05-13 10:00:07",
        "description": "Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier."
      },
      {
        "title": "Neuland Laboratories Ltd Opens 8.11% Higher in Sharp Gap Up, But Can the Technicals Support It?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-opens-strong-with-significant-gap-up-reflecting-positive-market-sentiment-3989062",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_gapup_3989062.png",
        "date": "2026-05-13 09:50:07",
        "description": ""
      },
      {
        "title": "Neuland Laboratories Ltd Reports Strong Quarterly Turnaround with Record Revenue and Profit Margins",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-reports-strong-quarterly-turnaround-with-record-revenue-and-profit-margins-3988334",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_fintrenddot_3988334.png",
        "date": "2026-05-13 08:00:05",
        "description": "Neuland Laboratories Ltd has delivered a remarkable financial turnaround in the quarter ended March 2026, posting record revenues and operating margins that mark a significant improvement from its previous quarters. The company’s financial trend score surged from a negative -16 to a very positive 28, signalling robust operational performance and renewed investor confidence."
      },
      {
        "title": "Neuland Laboratories Gains 9.65%: 4 Key Factors Driving the Week’s Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-gains-965-4-key-factors-driving-the-weeks-rally-3984224",
        "imagepath": "",
        "date": "2026-05-10 13:00:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Intraday high of Rs.16,460 with a 7.09% surge</p>\n                    <p><strong>5 May:</strong> Technical momentum shifts amid strong price rally</p>\n                    <p><strong>6 May:</strong> Mojo Grade upgraded to Hold as technicals improve</p>\n                    <p><strong>6 May:</strong> Technical momentum signals mildly bullish outlook</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.16,135.75</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.17,693.65</div>..."
      },
      {
        "title": "Neuland Laboratories Ltd Upgraded to Hold as Technicals Improve Despite Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/neuland-laboratories-ltd-upgraded-to-hold-as-technicals-improve-despite-financial-challenges-3977070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_mojoScore_3977070.png",
        "date": "2026-05-06 08:07:02",
        "description": "Neuland Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and institutional backing despite recent financial headwinds. The upgrade is driven primarily by improved technical indicators, stable quality metrics, and a cautious valuation stance amid mixed financial trends."
      }
    ],
    "total": 767,
    "sid": "229993",
    "stock_news_url": "https://www.marketsmojo.com/news/neuland-laboratories-229993"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "16-May-2026",
      "details": "Transcript of the Earnings Call conducted on May 12 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-May-2026",
      "details": "Copy of Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-May-2026",
      "details": "Copy of Newspaper Publication",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has declared <strong>120%</strong> dividend, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has announced <strong>4:25</strong> rights issue, ex-date: 13 Aug 14",
          "dt": "2014-08-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Neuland Laboratories Falls 6.35%: 4 Key Factors Driving the Weekly Decline

2026-05-17 13:00:04

Key Events This Week

11 May: Stock opens at Rs.17,548.30, declines 0.82%

12 May: Sharp drop of 3.12% amid low volume

13 May: Strong gap up and record quarterly results announced

14 May: Partial recovery with 1.51% gain

15 May: Week closes at Rs.16,570.70, down 0.79%

Week Open

Rs.17,548.30

Read full news article

Neuland Laboratories Ltd is Rated Buy

2026-05-17 10:10:03

Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Neuland Laboratories Ltd latest results good or bad?

2026-05-13 19:17:02

Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters. However, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf...

Read full news article

Neuland Laboratories Q4 FY26: Stellar Quarter Masks Valuation Concerns

2026-05-13 10:01:41

Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs, has delivered an exceptional fourth quarter for FY26, posting a net profit of ₹212.67 crores—a staggering 424.21% surge quarter-on-quarter and 664.72% year-on-year. The ₹21,766.42-crore market cap company saw revenues soar to ₹776.25 crores in Q4 FY26, marking a 76.54% sequential jump and 136.40% annual growth. However, the stock's muted response—down 0.21% to ₹16,965.40 following the results—suggests investors are grappling with the company's elevated valuation multiples, including a price-to-earnings ratio of 123 times trailing earnings.

Read full news article

Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance

2026-05-13 10:00:07

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier.

Read full news article

Neuland Laboratories Ltd Opens 8.11% Higher in Sharp Gap Up, But Can the Technicals Support It?

2026-05-13 09:50:07

Read full news article

Neuland Laboratories Ltd Reports Strong Quarterly Turnaround with Record Revenue and Profit Margins

2026-05-13 08:00:05

Neuland Laboratories Ltd has delivered a remarkable financial turnaround in the quarter ended March 2026, posting record revenues and operating margins that mark a significant improvement from its previous quarters. The company’s financial trend score surged from a negative -16 to a very positive 28, signalling robust operational performance and renewed investor confidence.

Read full news article

Neuland Laboratories Gains 9.65%: 4 Key Factors Driving the Week’s Rally

2026-05-10 13:00:04

Key Events This Week

4 May: Intraday high of Rs.16,460 with a 7.09% surge

5 May: Technical momentum shifts amid strong price rally

6 May: Mojo Grade upgraded to Hold as technicals improve

6 May: Technical momentum signals mildly bullish outlook

Week Open

Rs.16,135.75

Week Close

Rs.17,693.65

...

Read full news article

Neuland Laboratories Ltd Upgraded to Hold as Technicals Improve Despite Financial Challenges

2026-05-06 08:07:02

Neuland Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and institutional backing despite recent financial headwinds. The upgrade is driven primarily by improved technical indicators, stable quality metrics, and a cautious valuation stance amid mixed financial trends.

Read full news article

View All News